CC
ALNY icon

Casdin Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Casdin Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,000
Closed -$3.54M – 39
2023
Q3 		$3.54M Buy
+20,000
New +$3.82M 0.39% 28

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital's ALNY Position: Q1 2026 in Review

Casdin Capital held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 75,000 shares worth $24.8M. The position accounts for 1.88% of the portfolio, ranked #13.

Casdin Capital first reported a position in ALNY in Q4 2015 and has held it in 42 quarters since. The position peaked at $189M in Q3 2021. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Casdin Capital held 75,000 shares of Alnylam Pharmaceuticals worth $24.8M as of Q1 2026.
  • Casdin Capital left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up 1.88% of Casdin Capital's portfolio in Q1 2026, its #13 holding.
  • Casdin Capital first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • Casdin Capital's Alnylam Pharmaceuticals position peaked at $189M in Q3 2021.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.